Impact of PSMA PET/CT on initial staging and planning of definitive radiation therapy in prostate cancer
British Journal of Radiology · 01.06.2026 · 99 (1182) · 1125-1130
DOI: 10.1093/bjr/tqag057 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 10.03.2026. Verfasst von Rasha Elsaka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology and Nuclear Medicine Department, Alexandria University, Alexandria 21526, Egypt. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Radiotherapy Planning, Computer-Assisted. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objectives
Comparing risk grouping, target delineation, and dosimetric parameters between RT plans based on conventional imaging (CT and/or MRI pelvis with bone scan) versus 18F-PSMA PET/CT in the same patients.
Methods
A 75 newly diagnosed PCa patients treated with definitive RT between January 2019 and December 2022 at our center were included. Each underwent standard imaging and 18F-PSMA PET/CT. Two RT plans were generated; one from conventional imaging and another from PSMA PET/CT data using IMRT or RapidArc on the Eclipse (Varian, USA) system. Plans were compared regarding target volumes (TVs), dose-volume histograms (DVH), and doses to organs at risk (OARs).
Results
Mean age was 69.6 ± 8.1 years, and mean pretreatment PSA was 33.47 ± 42.05 ng/mL. Gleason score (GS) was 7 in 50.7% and 8–10 in 26.6%. PSMA-PET/CT altered TVs in 26 patients (34.7%). PSMA-based RT plans showed significantly higher rectal V60% (19.96% vs 18.1%, P = .024), femoral maximum dose (46.37 Gy vs 41.98 Gy, P = .006), and bowel maximum dose (54.7 Gy vs 46.3 Gy, P = .014). Upstaged patients had larger mean prostate volumes (77.53 ± 34.76 cc vs 59.76 ± 30.6 cc; P = .026).
Conclusion
18F-PSMA-PET/CT significantly impacts staging and RT planning in prostate cancer, leading to altered TVs and dosimetry, significantly in patients with larger prostates, but non significantly in patients with GS ≥ 8, and higher PSA levels. Advances in knowledge PSMA PET/CT meaningfully changes staging, TVs, and dosimetry. It highlights the modality’s value in improving accuracy in definitive RT planning.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Oncology and Nuclear Medicine Department, Alexandria University, Alexandria 21526, Egypt.
- Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Alexandria University, Alexandria 21526, Egypt.
- Radiological Sciences and Medical Imaging Department, Faculty of Applied Health Science Technology, Pharos University, Alexandria 21526, Egypt.
- Faculty of Allied Medical Science, Pharos University, Alexandria 21526, Egypt.
- Radiation Sciences Department, Medical Research Institute, Alexandria University, Alexandria 21526, Egypt.
ORCID-Profile: Hanady Hegazy
Zitieren
APA
Elsaka, R., Hegazy, H., Eldrieny, A., Kotb, M., Morsi, M., & Elsaid, A. (2026). Impact of PSMA PET/CT on initial staging and planning of definitive radiation therapy in prostate cancer. British Journal of Radiology, 99(1182), 1125-1130. https://doi.org/10.1093/bjr/tqag057
Vancouver
Elsaka R, Hegazy H, Eldrieny A, Kotb M, Morsi M, Elsaid A. Impact of PSMA PET/CT on initial staging and planning of definitive radiation therapy in prostate cancer. British Journal of Radiology. 2026;99(1182):1125-1130. doi:10.1093/bjr/tqag057
BibTeX
@article{Elsaka2026,
author = {Elsaka, Rasha and Hegazy, Hanady and Eldrieny, Ahmed and Kotb, Mahmoud and Morsi, Mohamed and Elsaid, Amr},
title = {Impact of PSMA PET/CT on initial staging and planning of definitive radiation therapy in prostate cancer},
journal = {British Journal of Radiology},
year = {2026},
volume = {99},
number = {1182},
pages = {1125--1130},
doi = {10.1093/bjr/tqag057}
}
EUVIMED